We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ixico Plc | LSE:IXI | London | Ordinary Share | GB00BFXR4C20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.75 | 8.50 | 9.00 | 8.75 | 8.725 | 8.75 | 4,640 | 08:00:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
19/7/2014 08:32 | IXICO, Phytopharm Brain health business builds growth platform Today, 8:32 AM | jollynews | |
19/6/2014 07:45 | Some good news for future and s/holders | ewads | |
06/6/2014 10:11 | Daniel Stewart Buy 62.50 62.50 132.00 132.00 Reiterates | skinny | |
06/6/2014 07:12 | Successful launch of Assessa® - significant progress in clinical trials and experimental medicine business IXICO plc (Ticker: IXI) ("IXICO" or the "Company"), the brain health company, today announces its unaudited interim results for the six months ended 31 March 2014. Highlights · Successful launch of Assessa®, our CE-marked digital healthcare platform for decision-support in dementia diagnosis o IXICO and partner InHealth providing selective access to Assessa® in the UK and Eire o Assessa® now available in the private healthcare sector through Re:Cognition Health Limited o Krish Ramakrisnan appointed as Vice President, Product Marketing with specific responsibility for the commercialisation of Assessa® o Further investment in the development and commercialisation of Assessa® · Expansion in clinical trials and experimental medicine business o Contracts signed with four new customers; IXICO has now been awarded contracts by nine of the top fifteen global pharmaceutical companies o International commercial and operational alliance signed with VirtualScopics of the US to deliver world-class services to pharmaceutical, biotech and academic customers and collaborators around the globe · Continuing business development in China o Memorandum of Understanding signed with Beijing Union Medical and Pharmaceutical General Corporation, the innovation arm of the Chinese Academy of Medical Sciences during the UK Prime Minister's trade mission to China o IXICO subsequently awarded its first Phase III clinical trial with a local Chinese pharmaceutical company o Asia developing as a key strategic priority for IXICO · Financial performance on budget and in-line with expectations o Revenues of £1.2 million and operating loss before non-recurring expenses of £0.6 million for the period o Total cash and money market investments of £4.0 million as at 31 March 2014 Recent Developments · Awarded a development contract by The Small Business Research Initiative for Healthcare for the development of a digital health application designed to support dementia sufferers post-diagnosis · Awarded two separate clinical trials with top fifteen pharmaceutical companies in Huntington's disease Derek Hill, IXICO's CEO, said: 'I am pleased to report a busy and highly significant period for IXICO, which included three landmark events in the Company's history. In October 2013, we successfully completed our reverse takeover of Phytopharm plc which provided the Company with additional funds with which to invest in developing and commercialising its technology. This was followed by the launch of our CE marked Assessa® diagnostic platform with a market-leading partner in December 2013. In March 2014, we announced our international commercial and operational alliance with VirtualScopics. Meanwhile, we continued to make excellent progress on our wider vision to translate our digital healthcare technology into a platform to support diagnosis of dementia. The commercialisation of Assessa® remains a top strategic priority and we are pleased to be signing up our first paying customers and will continue to invest in its development and use with key opinion leaders globally. We are continuing to explore partnerships with other businesses that are complementary to IXICO's current activity.' | skinny | |
12/3/2014 15:42 | Business Weekly - IXICO grabs global glory after Phytopharm rescue | aishah | |
11/3/2014 11:24 | 150k sell on the 7th probably taking them below 3%. Major Shareholders > 3% Invesco Asset Management 3,910,542 26.15 Imperial Innovations Group plc 1,722,273 11.52 Hardsteel Limited 847,148 5.67 Capital Number 1 Fund 735,023 4.92 Marcus Sarner 626,159 4.19 Derek Hill 477,169 3.19 | aishah | |
11/3/2014 10:42 | Watch out they still have a load more to sell which could drop price considerably, its happened before. | loobrush | |
11/3/2014 10:18 | Yes would be good if seller has done. | curlly | |
11/3/2014 10:15 | RNS that would explain why it didn't move up on Friday,With that out the way I see us at £1.00 plus a share quite quickly . | bckttsim | |
11/3/2014 09:55 | Some £10k plus buys early on I see. | bckttsim | |
11/3/2014 09:24 | 85 pence paid ,This is really going places today. | bckttsim | |
11/3/2014 09:18 | Steady buying.Some starting to see the true value here. | bckttsim | |
11/3/2014 08:54 | Now we have entered the Top list on ADVFN. | bckttsim | |
11/3/2014 08:51 | Ticked up again now 6.9% upYou need to be in to win ........as they say ! | bckttsim | |
11/3/2014 08:50 | Just about to post same ;-) Bought in yesterday, huge prospects | melodrama | |
11/3/2014 08:41 | Any moderate buying on this stock and watch it go. | bckttsim | |
11/3/2014 08:26 | A few trades and up we go. | bckttsim | |
11/3/2014 08:14 | A world class company in the making.This will MULTIBAG . | bckttsim | |
10/3/2014 16:11 | Transatlantic alliance changes game on drug trials | aishah | |
10/3/2014 15:52 | Our alliance partners like what they have doneVirtualScopics said it also increasingly is turning to partnerships with other companies to boost business, such as a deal with IXICO, a British medical image and analysis technology firm. According to VirtualScopics, the two companies "plan to form an international commercial and operational alliance, providing the clinical trials industry with global operational capabilities and a full range of therapeutic area and modality expertise. For VirtualScopics, this potential alliance enables us to access IXICO's expertise in neurology, European footprint, and complementary technologies to provide more comprehensive and scalable capabilities to our customers."That news apparently heartened investors. VirtualScopics stock gained nearly 2 percent on Friday, and was up more than 1 percent Monday morning, trading at $4.05. | bckttsim | |
10/3/2014 14:45 | The RNS Friday was late in the day on the International alliance with VirtualScopics So a lot people would have missed it.This is why no movement on price fri but has risen today.As more cotton on it's going to rise further. | bckttsim | |
10/3/2014 14:31 | This company is off the radar charts of many,It needs a bit of recognition . | bckttsim |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions